Dr. David J. Mazzo is the President and CEO of Caladrius Biosciences, a development stage, public biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, including ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes as well as CD34 cell therapy for ischemic repair in a variety of diseases including critical limb ischemia, coronary microvascular disfunction and refractory angina. He is a pharmaceutical executive and strategic leader with >30 years of broad international experience, working in both big pharma and emerging pharma in the USA, Canada, Europe and Japan. He is also a seasoned board director having served on the boards of all the companies for which he was CEO plus Essex Chimie AG (EU subsidiary of Schering-Plough), Avanir Pharmaceuticals and EyePoint Pharmaceuticals (formerly known as pSivida, Inc.), where he is chairman of the board. Dr. Mazzo earned a Ph.D. in Analytical Chemistry and an M.S. in Chemistry from the University of Massachusetts (Amherst). He also holds a B.S.(Chemistry) and a B.A. (Honors-Interdisciplinary Humanities) from Villanova University (Pennsylvania).